/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. The Bio Report
  2. Targeting Visceral Fat with RNA Therapeutics
Targeting Visceral Fat with RNA Therapeutics

Targeting Visceral Fat with RNA Therapeutics

The Bio Report · Sep 16, 2026

Beyond GLP-1s: An RNA therapy targets harmful visceral fat while preserving muscle, aiming to redefine success in obesity treatment.

The 70% First-Year Discontinuation Rate for GLP-1s Creates a Major Market for Better-Tolerated Therapies

Despite their efficacy, GLP-1s suffer from significant tolerability issues (GI side effects) and frequent dosing, leading a majority of patients to stop treatment within a year. This massive churn creates a substantial market opportunity for alternative mechanisms that offer a better patient experience with fewer side effects.

Targeting Visceral Fat with RNA Therapeutics thumbnail

Targeting Visceral Fat with RNA Therapeutics

The Bio Report·2 months ago

Wave Life Sciences’ RNA Therapy Targets Three Distinct Obesity Markets: Monotherapy, GLP-1 Combination, and Maintenance

Instead of directly competing with GLP-1s, the drug's novel fat-reducing mechanism allows for a flexible go-to-market strategy. It can serve as a standalone treatment for intolerant patients, an add-on to boost GLP-1 efficacy, or an 'off-ramp' to maintain weight loss after stopping an incretin drug.

Targeting Visceral Fat with RNA Therapeutics thumbnail

Targeting Visceral Fat with RNA Therapeutics

The Bio Report·2 months ago

Obesity Drug Success Should Be Judged on Visceral Fat Reduction, Not Just Scale Weight

The focus on total weight loss is misleading because it ignores dangerous muscle loss. True therapeutic success lies in selectively reducing visceral fat, which drives cardiometabolic risk, while preserving muscle. This represents a critical shift in clinical endpoints for next-generation obesity drugs.

Targeting Visceral Fat with RNA Therapeutics thumbnail

Targeting Visceral Fat with RNA Therapeutics

The Bio Report·2 months ago

Wave’s Obesity Drug Showed 14% Visceral Fat Reduction After a Single Low Dose in a Phase 1 Safety Trial

Phase 1 trials are designed to test safety, not efficacy. The fact that a single, low dose produced a clinically meaningful 14% reduction in visceral fat in healthy individuals is a powerful and unexpected early signal of the drug's potency and its direct mechanism of action on fat breakdown.

Targeting Visceral Fat with RNA Therapeutics thumbnail

Targeting Visceral Fat with RNA Therapeutics

The Bio Report·2 months ago

Proprietary RNA Chemistry Enables a 'Once-a-Year' Dosing Regimen, Creating a Key Competitive Advantage

Wave Life Sciences' differentiation lies in advanced chemistry, including stereochemistry control, that results in a more durable knockdown of the target gene. This translates into a powerful competitive advantage: an infrequent dosing schedule (once or twice yearly) that dramatically improves patient convenience compared to weekly GLP-1 injections.

Targeting Visceral Fat with RNA Therapeutics thumbnail

Targeting Visceral Fat with RNA Therapeutics

The Bio Report·2 months ago

Wave Life Sciences De-Risked Its Obesity Drug by Mimicking a Naturally Occurring 'Healthy' Gene Variant

The drug's target, the inhibin E gene, was identified from large-scale human genetic studies. Individuals with a natural loss-of-function variant in this gene exhibit a healthier cardiometabolic profile, providing strong human validation for the therapeutic approach before clinical trials even began, increasing the likelihood of success.

Targeting Visceral Fat with RNA Therapeutics thumbnail

Targeting Visceral Fat with RNA Therapeutics

The Bio Report·2 months ago